BACKGROUND: A retrospective analysis of treatment outcomes in @entity1 with @entity189 ( @entity189 ) was performed in which the newly revised 1997 American Joint Committee on @entity5 (AJCC) stage classification was applied and compared with the 1988 AJCC and Ho stage classifications, with emphasis on the predictive value of different staging systems in determining failure patterns in @entity189 . METHODS: Three hundred and twenty-four @entity1 with newly diagnosed @entity189 treated between September 1989 and August 1991 and originally staged according to Ho stage classification were re-staged according to the 1988 and 1997 AJCC stage classifications. In addition to stage grouping, @entity1 were also classified into the following prognostic categories to study the failure patterns: early disease group (T1-2N0-1), advanced @entity66 group (T3-4N0-1), advanced nodal disease group (T1-2N2-3), and advanced locoregional disease group (T3-4N2-3). The @entity1349 ( @entity1349 ), relapse-free survival (RFS), local relapse-free survival, nodal relapse-free survival, and distant metastases-free survival were compared among different stage groups and prognostic categories in the three staging systems. RESULTS: In the new AJCC system, the percentages of @entity1 with Stage I, II, III, and IV disease were 15.1%, 31.5%, 28.1%, and 25.3%, respectively, whereas most @entity1 were classified as having Stage IV disease (65.7%) in the old AJCC system and @entity5 (74.1%) in the Ho system. The 5 year @entity1349 rates in the 1997 AJCC Stage I, II, III, and IV disease were 97.7%, 78.7%, 79.5%, and 61.4%, respectively. The corresponding 5 year RFS rates were 95.7%, 64.7%, 54.5%, and 41.1%. Using the 1997 AJCC system to define the four prognostic categories, the early disease group had the lowest incidence of relapse (27.6%) and @entity204 (18.4%), whereas the advanced locoregional disease group had the highest incidence of relapse (61.4%) and @entity204 (43.2%). Both the advanced @entity66 group and the advanced nodal disease group had similar rates of relapse (46.7% vs. 47.2%), but local relapse was the major cause of failure in the former group (61.8%), whereas distant metastases was the major cause in the latter group (44%). CONCLUSIONS: Using the 1997 AJCC staging system, the authors observed a better distribution of @entity1 numbers as well as segregation of survival curves among different stage groups. Moreover, prognostic categories with distinct prognosis and failure patterns were definable by the new system, which has important implications in selecting appropriate @entity1 treatment strategies.

The predictive value of the 1997 American Joint Committee on @entity5 stage classification in determining failure patterns in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Stage II or III disease', 'Cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma', 'NPC'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['overall survival', 'OAS']
@entity189 :: (MESH:D002277,Disease) :: ['nasopharyngeal carcinoma']
